On May 28, Guardant Health rose 5.26% in regular trading, trading at $126.21 per share, with trading volume of $191 million.

On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an alternative option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.

This milestone follows closely after the FDA's recent approval of the company's Guardant360 Liquid CDx test as a companion diagnostic tool for non-small cell lung cancer and colorectal cancer therapies, which integrates genomic and epigenomic analysis through a single blood draw with 100x expanded genomic coverage.

Guardant Health is a precision oncology company that provides blood and tissue tests, data sets, and analytics. The company offers products including Guardant360, Shield Test, and GuardantINFINITY, serving both clinical and biopharmaceutical customers globally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)